vilobelimab
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pyoderma Gangrenosum
Conditions
Pyoderma Gangrenosum
Trial Timeline
May 16, 2019 → Jan 3, 2022
NCT ID
NCT03971643About vilobelimab
vilobelimab is a phase 2 stage product being developed by InflaRx for Pyoderma Gangrenosum. The current trial status is completed. This product is registered under clinical trial identifier NCT03971643. Target conditions include Pyoderma Gangrenosum.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03971643 | Phase 2 | Completed |
Competing Products
11 competing products in Pyoderma Gangrenosum
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| sisomicin | Merck | Approved | 85 |
| secukinumab 150 mg (2 injections per dose | Novartis | Phase 2 | 52 |
| Secukinumab | Novartis | Phase 1/2 | 41 |
| Deucravacitinib | Bristol Myers Squibb | Phase 1 | 32 |
| gevokizumab | XOMA | Phase 2 | 44 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 69 |
| gevokizumab | XOMA | Phase 3 | 69 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 69 |
| vilobelimab + Placebo | InflaRx | Phase 3 | 69 |
Other Products from InflaRx
vilobelimab + PlaceboPhase 3
69
IFX-1 + BSC + BSC + IFX-1 + SOC + Placebo + SOCPhase 2/3
57
Cohort A: vilobelimab + Cohort A: placebo + Cohort B: paridiprubart + Cohort B: placebo + Cohort C: bevacizumab + Cohort C: placeboPhase 2
44
IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC)Phase 2
44
Cohort C: bevacizumab + Cohort C: placeboPhase 2
44